Immatics N.V. Ordinary Shares (IMTX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMTX trades at $11.22 with a market cap of $1.45B and a P/E ratio of 0.00. IMTX moved +4.77% today. Year to date, IMTX is +15.08%; over the trailing twelve months it is +107.78%. Its 52-week range spans $3.30 to $12.41. Analyst consensus is strong buy with an average price target of $19.03. Rallies surfaces IMTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immatics Holds $521.5M Cash, Eyes 2026 Phase 3 SUPRAME Analyses for 2027 Launch: Immatics holds $521.5M in cash as of March 31, 2026, and expects interim and final Phase 3 SUPRAME analyses of anzu-cel in 2026 ahead of a planned 2027 launch. Immatics expects multiple 2026 readouts including IMA203CD8 and IMA402 data, plus launch of a PRAME TCR bispecific combination trial in sqNSCLC.
| Metric | Value |
|---|---|
| Price | $11.22 |
| Market Cap | $1.45B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.41 |
| 52-Week Low | $3.30 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
8 analysts cover IMTX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.03.